Examples of how the pharmaceutical industries distort the evidence of drug safety: the case of pioglitazone and the bladder cancer issue

Pharmacoepidemiol Drug Saf. 2016 Feb;25(2):212-4. doi: 10.1002/pds.3925. Epub 2015 Nov 30.

Authors

Jean-Luc Faillie^{1

2}, Dominique Hillaire-Buys^{1

3}

Affiliations

¹ Department of Medical Pharmacology and Toxicology, University Hospital CHRU Montpellier, Montpellier, France.
² Department of Pharmacoepidemiology, INSERM U1027, Faculty of Medicine, Paul Sabatier University, Toulouse, France.
³ INSERM U1058, Faculty of Medicine, Montpellier, France.

PMID: 26617411
DOI: 10.1002/pds.3925

No abstract available

Keywords: drug safety; pharmaceutical industry; pharmacoepidemiology; pharmacovigilance; pioglitazone.

Publication types

Review

MeSH terms

Animals
Drug Industry / legislation & jurisprudence*
Drug Industry / standards
Humans
Hypoglycemic Agents / adverse effects*
Pharmacoepidemiology / trends
Pioglitazone
Scientific Misconduct / legislation & jurisprudence*
Scientific Misconduct / trends
Thiazolidinediones / adverse effects*
Urinary Bladder Neoplasms / chemically induced*
Urinary Bladder Neoplasms / epidemiology*

Substances

Hypoglycemic Agents
Thiazolidinediones
Pioglitazone